구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Autologous CAR-T cells |
Overview Company | Hebei Senlang Biotechnology Inc., Ltd. |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Leukemia; Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral particles for optimal NK cell transduction |
MoA Mechanism | targeting specific tumor-associated antigen |
MoA Biomarker | CD19 CAR-T cells can effectively treat high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.. The best way to monitor Chimeric Antigen Receptor (CAR)-T cells persistence and expansion in vivo after infusion, and the significance of observed fluctuations over time remains controversial. As living drugs, these therapies do not follow classical … |
Toxicology CRS | grade 1-2 |
Clinical Safety signal | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.. The best way to monitor Chimeric Antigen Receptor (CAR)-T cells persistence and expansion in vivo after infusion, and the significance of observed fluctuations over time remains controversial. As living drugs, these therapies do not follow classical … |
Clinical Selected reported efficacy | ORR 80.3% |
Clinical Reported ORR | 80.3% |
Clinical Reported PFS | 9.03 |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03483103 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03483103 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Autologous CAR-T cells |
Overview Company | Hebei Senlang Biotechnology Inc., Ltd. |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Leukemia; Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral particles for optimal NK cell transduction |
MoA Mechanism | targeting specific tumor-associated antigen |
MoA Biomarker | CD19 CAR-T cells can effectively treat high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.. The best way to monitor Chimeric Antigen Receptor (CAR)-T cells persistence and expansion in vivo after infusion, and the significance of observed fluctuations over time remains controversial. As living drugs, these therapies do not follow classical … |
Toxicology CRS | grade 1-2 |
Clinical Safety signal | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.. The best way to monitor Chimeric Antigen Receptor (CAR)-T cells persistence and expansion in vivo after infusion, and the significance of observed fluctuations over time remains controversial. As living drugs, these therapies do not follow classical … |
Clinical Selected reported efficacy | ORR 80.3% |
Clinical Reported ORR | 80.3% |
Clinical Reported PFS | 9.03 |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03483103 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03483103 |
추천 비교
추천 비교